Circulating Neurofilament is Linked with Morbid Obesity, Renal Function, and Brain Density

Overview

Journal Sci Rep

Specialty Science

Date 2022 May 13

PMID 35551210

Authors

Eleni Rebelos

Eero Rissanen

Marco Bucci

Olli Jaaskelainen

Miikka-Juhani Honka

Lauri Nummenmaa

Diego Moriconi

Sanna Laurila

Paulina Salminen

Sanna-Kaisa Herukka

Tarun Singhal

Pirjo Nuutila

Affiliations

Soon will be listed here.

Abstract

Neurofilament light chain (NfL) is a novel biomarker reflecting neuroaxonal damage and associates with brain atrophy, and glial fibrillary acidic protein (GFAP) is a marker of astrocytic activation, associated with several neurodegenerative diseases. Since obesity is associated with increased risk for several neurodegenerative disorders, we hypothesized that circulating NfL and GFAP levels could reflect neuronal damage in obese patients. 28 morbidly obese and 18 lean subjects were studied with voxel based morphometry (VBM) MRI to assess gray and white matter densities. Serum NfL and GFAP levels were determined with single-molecule array. Obese subjects were re-studied 6 months after bariatric surgery. Morbidly obese subjects had lower absolute concentrations of circulating NfL and GFAP compared to lean individuals. Following bariatric surgery-induced weight loss, both these levels increased. Both at baseline and after weight loss, circulating NfL and GFAP values correlated inversely with eGFR. Cross-sectionally, circulating NfL levels correlated inversely with gray matter (GM) density, and this association remained significant also when accounting for age and total eGFR. GFAP values did not correlate with GM density. Our data suggest that when determining circulating NfL and GFAP levels, eGFR should also be measured since renal function can affect these measurements. Despite the potential confounding effect of renal function on NfL measurement, NfL correlated inversely with gray matter density in this group of subjects with no identified neurological disorders, suggesting that circulating NfL level may be a feasible biomarker of cerebral function even in apparently neurologically healthy subjects.

Citing Articles

Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting.

De Meyer S, Blujdea E, Schaeverbeke J, Adamczuk K, Vandenberghe R, Poesen K Alzheimers Dement (Amst). 2025; 17(1):e70071.

PMID: 39886322 PMC: 11780118. DOI: 10.1002/dad2.70071.

Exploring the Link Between Renal Function Fluctuations Within the Physiological Range and Serum/CSF Levels of NfL, GFAP, tTAU, and UCHL1.

Koerbel K, Yalachkov Y, Rotter T, Schaller-Paule M, Schaefer J, Friedauer L Int J Mol Sci. 2025; 26(2).

PMID: 39859463 PMC: 11765624. DOI: 10.3390/ijms26020748.

Association of weight-adjusted waist index (WWI) and a body shape index (ABSI) with serum neurofilament light chain levels in a national study of U.S. adults.

Yan Z, Gu Q, Yin H, Yi M, Wang X, Sun R Eat Weight Disord. 2024; 29(1):76.

PMID: 39612146 PMC: 11607027. DOI: 10.1007/s40519-024-01706-z.

Plasma Biomarkers of Alzheimer's Disease and Neurodegeneration According to Sociodemographic Characteristics and Chronic Health Conditions.

Zheng H, Wu Z, Mielke M, Murray A, Ryan J J Prev Alzheimers Dis. 2024; 11(5):1189-1197.

PMID: 39350363 PMC: 11436401. DOI: 10.14283/jpad.2024.142.

Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.

Tortosa-Carreres J, Cubas-Nunez L, Sanz M, Castillo-Villalba J, Gasque-Rubio R, Carratala-Bosca S Neurol Sci. 2024; 46(2):845-853.

PMID: 39307881 DOI: 10.1007/s10072-024-07772-6.

References

Middeldorp J, Hol E . GFAP in health and disease. Prog Neurobiol. 2011; 93(3):421-43. DOI: 10.1016/j.pneurobio.2011.01.005. View

Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P . Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther. 2018; 10(1):71. PMC: 6064615. DOI: 10.1186/s13195-018-0404-9. View

Profenno L, Porsteinsson A, Faraone S . Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2009; 67(6):505-12. DOI: 10.1016/j.biopsych.2009.02.013. View

Tojo A, Kinugasa S . Mechanisms of glomerular albumin filtration and tubular reabsorption. Int J Nephrol. 2012; 2012:481520. PMC: 3363986. DOI: 10.1155/2012/481520. View

Kokubo Y, Uchida K, Kobayashi S, Yayama T, Sato R, Nakajima H . Herniated and spondylotic intervertebral discs of the human cervical spine: histological and immunohistological findings in 500 en bloc surgical samples. Laboratory investigation. J Neurosurg Spine. 2008; 9(3):285-95. DOI: 10.3171/SPI/2008/9/9/285. View

Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M . Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018; 8(1):14798. PMC: 6172254. DOI: 10.1038/s41598-018-33158-8. View

Heller C, Foiani M, Moore K, Convery R, Bocchetta M, Neason M . Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020; 91(3):263-270. DOI: 10.1136/jnnp-2019-321954. View

Ashburner J . A fast diffeomorphic image registration algorithm. Neuroimage. 2007; 38(1):95-113. DOI: 10.1016/j.neuroimage.2007.07.007. View

Oeckl P, Halbgebauer S, Anderl-Straub S, Steinacker P, Huss A, Neugebauer H . Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. J Alzheimers Dis. 2018; 67(2):481-488. DOI: 10.3233/JAD-180325. View

10.

Rebelos E, Dadson P, Oikonen V, Iida H, Hannukainen J, Iozzo P . Renal hemodynamics and fatty acid uptake: effects of obesity and weight loss. Am J Physiol Endocrinol Metab. 2019; 317(5):E871-E878. DOI: 10.1152/ajpendo.00135.2019. View

11.

Vagberg M, Norgren N, Dring A, Lindqvist T, Birgander R, Zetterberg H . Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction. PLoS One. 2015; 10(8):e0135886. PMC: 4552591. DOI: 10.1371/journal.pone.0135886. View

12.

Khalil M, Pirpamer L, Hofer E, Voortman M, Barro C, Leppert D . Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020; 11(1):812. PMC: 7010701. DOI: 10.1038/s41467-020-14612-6. View

13.

Gonzalez-Garcia I, Garcia-Caceres C . Hypothalamic Astrocytes as a Specialized and Responsive Cell Population in Obesity. Int J Mol Sci. 2021; 22(12). PMC: 8228119. DOI: 10.3390/ijms22126176. View

14.

Akamine S, Marutani N, Kanayama D, Gotoh S, Maruyama R, Yanagida K . Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep. 2020; 10(1):20350. PMC: 7683708. DOI: 10.1038/s41598-020-76990-7. View

15.

Du Bois D, Du Bois E . A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989; 5(5):303-11; discussion 312-3. View

16.

Ho A, Raji C, Becker J, Lopez O, Kuller L, Hua X . Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol Aging. 2010; 31(8):1326-39. PMC: 3197833. DOI: 10.1016/j.neurobiolaging.2010.04.006. View

17.

Thaler J, Yi C, Schur E, Guyenet S, Hwang B, Dietrich M . Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 2011; 122(1):153-62. PMC: 3248304. DOI: 10.1172/JCI59660. View

18.

Buse J, Caprio S, Cefalu W, Ceriello A, Del Prato S, Inzucchi S . How do we define cure of diabetes?. Diabetes Care. 2009; 32(11):2133-5. PMC: 2768219. DOI: 10.2337/dc09-9036. View

19.

Raji C, Ho A, Parikshak N, Becker J, Lopez O, Kuller L . Brain structure and obesity. Hum Brain Mapp. 2009; 31(3):353-64. PMC: 2826530. DOI: 10.1002/hbm.20870. View

20.

Walther K, Birdsill A, Glisky E, Ryan L . Structural brain differences and cognitive functioning related to body mass index in older females. Hum Brain Mapp. 2009; 31(7):1052-64. PMC: 6870943. DOI: 10.1002/hbm.20916. View